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Ophthalmology Volume 121, Number 7, July 2014that environmental factors such as smoking contribute to risk of
vision loss and CNV in AMD.3 Although there has been
progress in understanding risk factors for CNV in AMD, there is
a relative paucity of data for CNV owing to other causes such
as OHS.
The OHS-CNV patients were more likely to have a history of
smoking than the OHS-control subjects. Smoking is a reported
risk factor for a number of conditions, including the onset of
exudative AMD from nonexudative AMD, and the development
of polypoidal choroidal vasculopathy.3,4 A recent study from the
same region as this study also reported the odds for CNV asso-
ciated with OHS are 3 times higher in smokers.5 Our data also
yielded a signiﬁcantly higher incidence of cigarette smoking in
patients with OHS-CNV versus OHS-control patients. This
ﬁnding holds clinical value, in that counseling OHS patients
without CNV on smoking cessation may decrease their risk of
developing CNV.
This study has limitations. First, the number of subjects
enrolled in this study is small compared with the larger sample
sizes utilized in assessing these genes in AMD.1,5 However, OHS
is less common than AMD and enrolling asymptomatic subjects
without other ocular disease to prompt an eye examination is
challenging. This introduces sample bias in that the control
subjects presented to the retinal service for other concerns
(ﬂoaters, posterior vitreous detachment, retinal tear/detachment,
etc). In addition, there was a signiﬁcant difference in age between
the OHS-CNV and OHS-control groups, with the control group
being older. A recent study found an increase risk associated with
age and CNV in OHS patients, which was not reﬂected in this
study.5
In conclusion, this study did not show a correlation between
ARMS2, C3, MT-NDH2, and CFH alleles in the development of
CNV associated with OHS. There was a signiﬁcantly higher inci-
dence of cigarette smoking in patients with OHS-CNV versus
OHS-control patients. This study suggests that ARMS2, C3, MT-
NDH2, and CFH may not play a role in CNV in OHS. Further
studies are needed to investigate factors and the pathogenesis of
CNV in OHS.
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Development and Validation of
Quality-of-Life Questionnaires for
Birdshot ChorioretinopathyBirdshot chorioretinopathy (BCR) is a rare form of chronic pos-
terior uveitis, usually requiring long-term, systemic immunosup-
pression.1 The severe impact of the disease on acuity, visual ﬁeld,
color discrimination, and electrodiagnostics is well-documented,1,2
but studies on quality of life (QoL) have been limited. Furthermore,
existing QoL tools fail to capture the unique and wide range of
symptoms associated with BCR and BCR medications.Methods
Ethical approval was granted by the Royal Free London Hospital.
All procedures, such as prior informed consent, were conducted in
accordance with the Declaration of Helsinki.
Item development was via face-to-face meetings of the Item
Generation Group (composed of 2 patients with BCR, a consul-
tant ophthalmologist, and a psychologist). From this bank, 3
questionnaires were derived: the Birdshot Disease & Medication
Symptoms Questionnaire (BD&MSQ) with 43 items, the QoL
impact of BCR (QoL BCR) with 25 items, and the QoL impact of
BCR medication (QoL Meds) with 25 items. The content of the 2
QoL questionnaires was similar, except that the QoL BCR
focused on the daily impact of experiences attributable to the
disease and the QoL Meds focused on the daily impact of expe-
riences attributable to medication. Four-point Likert scales were
used, with lower scores indicating worse QoL. The 3 question-
naires were then administered to a second groupd8 volunteers
with BCR and 1 person with no eyesight problemsdas an on-line
survey. Participants and Item Generation Group members were
selected in accordance with the usual standards for survey
methodology.3
A factor analysis of the questionnaires was conducted to reﬁne
their structure. The thresholds for acceptability were: Kaiser-
Meyer-Olkin  0.6; Cronbach’s a  0.7, and the factor loading
threshold of >0.6.4 All statistical analyses were done using SPSS
21 (IBM Corp, Armonk, NY).
Members of BCR support groups and a community control
group were invited by email to participate in an online
questionnaire.
ReportsResults
Out of 292 support group members with BCR, 152 responded, a
response rate of 52%. Seventy-three percent (111 of 152) were
women. The age range was 29 to 76 years old, with a mean ( SD)
of 53.129.63 SD.
Of the 33 healthy community controls, it was possible to closely
match 18 of them with the BCR group for age and sex. The
matched controls had healthy eyesight apart from corrected
refractive error.
In the development of the BD&MSQ, after incomplete re-
sponses were eliminated, there were 141 BCR participants. Factor
analysis found 21 items forming 8 factors, 2 factors representing a
Birdshot disease symptoms domain, and 6 representing a medica-
tion symptoms domain. Together, these accounted for 57.75% of
the variance in scoring after extraction.
In the development of the QoL BCR, after incomplete re-
sponses were eliminated, there were 150 participants. Factor
analysis revealed 20 items forming four factors, accounting for
71.98% of the total variance.
In the development of the QoL Meds, after incomplete re-
sponses were eliminated, there were 126 participants. (This
number is lower than the other 2 questionnaires because
fewer participants reported medication use). Three factors were
found, consisting of 12 items, accounting for 70.1% of the total
variance.
For all 3 questionnaires, the thresholds for acceptability for
Kaiser-Meyer-Olkin, Cronbach’s a, and factor loadings were met
or exceeded. The subscales for the 3 questionnaires that resulted
from the factor analyses are shown in Table 1 (available at
www.aaojournal.org).
Construct validity was assessed by comparing the BCR group
and control group using Wilcoxon’s tests. Table 2 (available at
www.aaojournal.org) shows that the BCR group scored
signiﬁcantly lower than controls on the BD&MSQ and QoL
BCR scales and subscales, at a minimum P< 0.01. The pro-
ﬁle of non-BCR medication was similar in both groups. Figure 1
(available at www.aaojournal.org) shows box-and-whisker plots
for the total scores for the 2 scales. (Comparison was not possible
for the QoL Meds because controls did not take BCR medication).
Construct validity was further assessed by comparing outcomes
in BCR patients taking different amounts of prednisolone daily.
Using analysis of covariance to control for any effect of the
duration of time since diagnosis, patients with BCR taking >10 mg
of prednisolone daily had signiﬁcantly worse BD&MSQ (P< 0.01)
and QoL BCR (P< 0.05), and non-signiﬁcantly worse QoL Meds
scores, compared with patients with BCR taking a lower dose or no
dose of prednisolone daily.
Concurrent validity was also assessed. For the BCR partici-
pants, there was a strong negative correlation between the Visual
Function Questionnaire Utility Index health state classiﬁcation5
and each of the new measures at a minimum of r ¼ 0.546,
P< 0.000001, indicating acceptable concurrent validity.
Discussion
In this study, we describe the development of 3 novel patient-
reported outcome measures (PROMs) for BCR, directed toward
capturing (a) key symptoms of BCR and symptoms of medication
for BCR (BD&MSQ), (b) QoL (QoL BCR), and (c) the impact of
BCR medication on QoL (QoL Meds), in this rare but debilitatingcondition. In addition to providing the ﬁrst disease-speciﬁc
PROMs for use in BCR, this study provides an example of how
PROMs can be developed for even rare conditions.
These new instruments (available from the authors) may be of
value in clinical trials for this condition, with a view to assessing
change in symptoms and QoL arising from either disease or
medication. When using the BD&MSQ, we suggest that the 2
domainsddisease symptoms and medication symptomsdbe
scored separately, because each provide important independent
information. The medians shown in Table 2 (available at
www.aaojournal.org) for each domain and subscale can act as a
guide to the severity of QoL problems at baseline. For example,
a BCR patient who scores an average of 2.67 on the Birdshot
disease domain of the BD&MSQ can be considered to be
experiencing a typical level of QoL difﬁculty for BCR patients.
Validity and reliability measures indicate that these tools have
excellent psychometric properties and so can be used with
conﬁdence for patient reporting of symptoms and QoL in BCR.
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Adult Ophthalmology Inpatient
Consults at a Tertiary Care Teaching
HospitalOphthalmology consultation is commonly requested for inpatients
in a tertiary hospital,1e4 and there is often lack of familiarity with
ocular pathology among other medical professionals.3,5 This study
was designed to identify the characteristics of inpatient consulta-
tions performed at an adult tertiary care hospital and recommend
guidelines for developing an ophthalmology consult service and
resident consult curriculum.1489
Table 1. Items for the ﬁnal versions of the Birdshot Disease & Medication Symptoms Questionnaire (BD&MSQ), QoL impact of BCR
(QoL BCR), and QoL impact of BCR medication (QoL Meds).
Subscale BD&MSQ Subscale QoL BCR Subscale QoL Meds
Lights
Vision
Fluttering lights Mood and
relationships
Anger Mood and relationships
Vision
Unreasonable behavior
Flashing lights Depression Personal relationships
Simple repeat
pattern
Irritability Being a good family
member
Loss of night vision Ability to socialize Anger
Skin
Poor light-dark
adapt
Tearfulness Irritability
Loss of color Frustration Using a computer
Lack of contrast Anxiety Reading
Skin lesions Personal relationships Driving
Skin discoloration Professional and work
relationships
Watching TV
Lumps under skin Ability to focus Low mood Depression
Anxiety
Body pain Painful muscles Daily activities Watching TV Tearfulness
Pain in legs Using a computer
Aching joints Reading
Working
Breathless &
Shaky
Shaking
Breathing difﬁculty Unhappy Families Feeling violent
Mood Impending doom Unreasonable behavior
Depression Being a good family member
Sleep Disturbed sleep
Constantly tired Feeling unwell Nausea
Hair loss Loss of eyebrows Headache
Loss of hair Unwell
Over-consuming alcohol
Reports
1489.e1
Table 2. Differences between the Groups of 18 Birdshot Chorioretinopathy (BCR) and Healthy Controls Matched for Age and Sex, for
Birdshot Disease & Medication Symptoms Questionnaire (BD&MSQ) and QoL Impact of BCR (QoL BCR) Scores
Outcome Measure Group Median Interquartile Range (Range) Wilcoxon’s Z
BD&MSQ vision BCR 2.67 1.50 (1.1e3.8) 3.623***
Control 4.00 0.33 (2.8e4.0)
BD&MSQ lights BCR 2.67 1.00 (1.0e3.7) 3.735***
Control 4.00 0.00 (3.7e4.0)
BD&MSQ mood BCR 3.00 1.50 (1.0e4.0) 3.091**
Control 4.00 0.50 (2.5e4.0)
BD&MSQ body pain BCR 2.67 1.00 (1.0e4.0) 2.642**
Control 4.00 0.67 (2.3e4.0)
BD&MSQ hair loss BCR 3.00 1.50 (1.5e4.0) 3.015**
Control 4.00 0.00 (2.0e4.0)
BD&MSQ skin BCR 3.00 1.33 (2.0e4.0) 3.226**
Control 4.00 0.00 (3.3e4.0)
BD&MSQ sleep BCR 2.00 1.50 (1.0e4.0) 2.166*
Control 3.00 2.00 (1.0e4.0)
BD&MSQ total score BCR 2.76 0.56 (1.9e3.9) 3.363***
Control 3.76 0.48 (3.29e4.0)
QoL BCR mood and relationships BCR 2.40 1.30 (1.7e4.0) 3.416***
Control 3.90 0.10 (2.8e4.0)
QoL BCR daily activities BCR 2.50 1.75 (1.0e4.0) 3.250**
Control 3.75 0.50 (2.5e4.0)
QoL BCR unhappy families BCR 3.67 0.67 (2.3e4.0) 2.966**
Control 4.00 0.00 (4.0e4.0)
QoL BCR feeling unwell BCR 3.25 1.50 (2.0e4.0) 3.300***
Control 4.00 0.00 (3.8e4.0)
QoL BCR total score BCR 2.93 0.95 (2.2e4.0) 3.461***
Control 3.91 0.18 (3.3e4.0)
*P< 0.05;
**P< 0.01;
***P< 0.001. Signiﬁcance values are 2-tailed.
Figure 1. Box and whisker plot showing Birdshot Disease & Medication
Symptoms Questionnaire (BD&MSQ) and the quality of life (QoL) impact
of BCR (QoL BCR) scores in the Birdshot chorioretinopathy (BCR) group
(white boxes) compared with age- and sex-matched controls (shaded
boxes).
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